New combo therapy aims to stop rare bone cancer from spreading
NCT ID NCT07115667
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests whether combining radiation with a bispecific antibody called CM336 can safely treat solitary bone plasmacytoma, a rare plasma cell tumor that often turns into multiple myeloma. The study will enroll 21 adults with mild bone marrow involvement. Researchers will monitor side effects, especially immune overreactions, and track how long participants stay cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BCMA/CD3 bispecific antibody (CM336) combined with radiation therapy
What this could lead to
If successful, this combination could offer a new treatment option that delays or prevents progression to multiple myeloma for people with solitary bone plasmacytoma.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply broadly. The bispecific antibody can cause serious side effects like cytokine release syndrome (CRS) and nerve toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLITARY BONE PLASMACYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
RECRUITINGTianjin, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••